Granted Patent
B2
US 12,589,124 · App. 17/910,852 · Granted Mar 31, 2026
Bifidobacterium longum
Assignee:
PRECISIONBIOTICS GROUP LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of an infection in a subject caused by a coronavirus such as SARS-CoV-2. They are also useful in the prophylaxis of a secondary bacterial infection associated with an infection in a subject caused by a coronavirus, especially a subject who is susceptible to respiratory infections.
Claims (28)
1 . A method for the treatment of a coronavirus infection in a subject, the method comprising administering to the subject in need thereof a formulation comprising at least one Bifidobacterium longum strain or a cell wall fraction isolated from a Bifidobacterium longum strain,
wherein the coronavirus infection is a SARS-CoV-2 infection,
wherein a genome of the at least one Bifidobacterium longum strain is not manipulated to produce acquisition or loss of a gene, and
wherein the at least one Bifidobacterium longum strain is selected from one or more of the strain having the accession number NCIMB 41003, the strain having the accession number NCIMB 41715, the strain having the accession number NCIMB 41713, or the strain having the accession number NCIMB 42020.
2 . A method of claim 1 , wherein the coronavirus infection is caused by a coronavirus that is SARS-CoV-2, and wherein the Bifidobacterium longum or cell wall fraction
attenuates a IP-10 response to the coronavirus,
enhances a type III interferon response to the coronavirus,
enhances a interferon lambda response to the coronavirus,
suppresses a interferon type I response to the coronavirus,
suppresses a interferon alpha response to the coronavirus,
suppresses a interferon beta response to the coronavirus, and/or
enhances a surfactant protein D response to the coronavirus.
3 . A method of claim 1 , wherein the subject
has been diagnosed with an inflammatory lung disease,
is an acute respiratory distress syndrome (ARDS) patient,
is an asthma patient,
is obese,
is a chronic obstructive pulmonary disease (COPD) patient, and/or
is an elderly person greater than 60 years of age.
4 . A method of claim 1 , wherein the formulation further comprises Vitamin D.
5 . A method of claim 1 , wherein the formulation is in the form of a chewable or dissolvable tablet, a nasal spray, or a spray for spraying orally into a nasopharynx region of the subject.
6 . A method of claim 1 , wherein the Bifidobacterium longum strain is in the form of viable cells, non-viable cells, or both viable cells and non-viable cells.
7 . A method of claim 1 , wherein the Bifidobacterium longum strain is in the form of a freeze-dried powder.
8 . A method of claim 1 , wherein the Bifidobacterium longum strain is present in an amount of more than 10 6 cfu per gram of the formulation.
9 . A method of claim 1 , wherein the formulation further comprises Vitamin D, and the Vitamin D is present in an amount of at least 5 μg.
10 . A method of claim 1 , wherein the formulation further comprises an ingestible carrier.
11 . A method of claim 1 , wherein the formulation further comprises a probiotic material, a prebiotic material, or both a probiotic material and a prebiotic material.
12 . A method of claim 4 , wherein the formulation further comprises a protein, a peptide, a lipid, a carbohydrate, another vitamin, a mineral, a trace element, or a combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 25, 2022
From: GROEGER, DAVID; KIELY, BARRY
To: PRECISIONBIOTICS GROUP LIMITED
Reel/Frame 061206/0094 →
Priority Claims (3)
EP 20163197
· Mar 13, 2020
· regional
EP 21160580
· Mar 3, 2021
· regional
EP 21160660
· Mar 4, 2021
· regional
Continuity (1)
References Cited (157)
US 4157278A
· Ross et al.
· 1979
[cited by applicant]
US 4464362A
· Kludas et al.
· 1984
[cited by applicant]
US 20050100559A1
· Myatt
· 2005
[cited by examiner]
US 20090060878A1
· Clymer et al.
· 2009
[cited by applicant]
US 20090196921A1
· Ebel et al.
· 2009
[cited by applicant]
US 20120128644A1
· Hillman
· 2012
[cited by examiner]
US 20120201798A1
· Kekkonen et al.
· 2012
[cited by applicant]
US 20130165470A1
· Isfort
· 2013
[cited by applicant]
US 20160250265A1
· Petit et al.
· 2016
[cited by applicant]
AU 2010288546B2
· 2015
[cited by applicant]
CN 1433811A
· 2003
[cited by applicant]
CN 102321187A
· 2012
[cited by applicant]
EP 2181703A1
· 2010
[cited by applicant]
EP 2455092A1
· 2012
[cited by applicant]
JP 2005508617A
· 2005
[cited by applicant]
JP 2007169200A
· 2007
[cited by applicant]
JP 2010522552A
· 2010
[cited by applicant]
JP 2010522553A
· 2010
[cited by applicant]
JP 2013507431A
· 2013
[cited by applicant]
JP 2017081853A
· 2017
[cited by applicant]
RU 2151606C1
· 2000
[cited by applicant]
RU 2216588C1
· 2004
[cited by applicant]
RU 2314341C1
· 2008
[cited by applicant]
RU 2557310C2
· 2013
[cited by applicant]
WO 2008053444A2
· 2008
[cited by applicant]
WO 2008053444A3
· 2008
[cited by applicant]
WO WO2009100331A2
· 2009
[cited by examiner]
WO 2012029064A1
· 2012
[cited by applicant]
WO 2012062780A1
· 2012
[cited by applicant]
WO 2015021530A1
· 2015
[cited by applicant]
WO 2015140299A1
· 2015
[cited by applicant]
WO 2016009377A1
· 2016
[cited by applicant]
WO 2016120320A1
· 2016
[cited by applicant]
WO 2016142767A1
· 2016
[cited by applicant]
WO 2017032897A1
· 2017
[cited by applicant]
WO 2018047106A1
· 2018
[cited by applicant]
WO 2018158306A1
· 2018
[cited by applicant]
WO 2018158306A8
· 2018
[cited by applicant]
WO 2018158309A1
· 2018
[cited by applicant]
WO 2018168449A2
· 2018
[cited by applicant]
WO WO2021168577A1
· 2021
[cited by examiner]
Xu et al., “Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome”, Lancet Respir Med. Feb. 18, 2020. pii: S2213-2600(20)30076-X.
[cited by applicant]
Leth-Larsen et al., “The SARS Coronavirus Spike Glycoprotein is Selectively Recognized by Lung Surfactant Protein D and Activates Macrophages”, Immunobiology. 2007;212(3):201-11. Epub Jan. 26, 2007.
[cited by applicant]
Xu et al., “Management of COVID-19: the Zhejiang experience”, Zhejiang Da Xue Xue Bao Yi Xue Ban. Feb. 21, 2020;49(2):147-57, DOI: 10.3785/j.issn.1008-9292.2020.02.02. PMID: 32391658; PMCID: PMC8800711.
[cited by applicant]
Channappanavar et al., “Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-COV-Infected Mice”, Cell Host Microbe. Feb. 10, 2016;19(2):181-93.
[cited by applicant]
Channappanavar et al., “IFN-I Response Timing Relative to Virus Replication Determines MERS Coronavirus Infection Outcomes”, J Clin Invest. Jul. 29, 2019;130:3625-39.
[cited by applicant]
Ding et al., “The Clinical Pathology of Severe Acute Respiratory Syndrome (SARS): a Report from China”, J Pathol 2003; 200: 282-89.
[cited by applicant]
Ng et al., “Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates”, Apr. 2014. Am J Pathol 2016; 186: …
[cited by applicant]
Thevarajan et al., “Breadth of Concomitant Immune Responses Underpinning Viral Clearance and Patient Recovery in a Non-Severe Case of COVID-19”, medRxiv 2020.02.20.20025841; doi: https://doi.org/10.1101/2020.02.20.20025…
[cited by applicant]
Song et al., “From SARS to MERS”, Thrusting Coronaviruses into the Spotlight, Jan. 2019; 11(1): 59.
[cited by applicant]
Scheuplein et al., “High Secretion of Interferons by Human Plasmacytoid Dendritic Cells Upon Recognition of Middle East Respiratory Syndrome Coronavirus”, J Virol. Apr. 2015;89(7):3859-69. doi: 10.1128/JVI.03607-14.
[cited by applicant]
Zhao et al., “Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses”, J Virol. Feb. 26, 2018;92(6). pii: e01535-17. doi: 10.1128/JVI.01535-17. P…
[cited by applicant]
Channappanavar et al., “Pathogenic Human Coronavirus Infections: Causes and Consequences of Cytokine Storm and Immunopathology”, Semin Immunopathol (2017) 39:529-539, DOI: 10.1007/s00281-017-06290x.
[cited by applicant]
Liao et al., “The Landscape of Lung Bronchoalveolar Immune Cells in COVID-19 Revealed by Single-cell RNA Sequencing”, Institute for Hepatology, National Clinical Research Center for Infectious Disease, China, MedRXIV, F…
[cited by applicant]
Liu et al., “Overlapping and Discrete Aspects of the Pathology and Pathogenesis of the Emerging Human Pathogenic Coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV”, J Med Virol. Feb. 13, 2020.
[cited by applicant]
Blanco-Melo et al., “Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19” Cell. Epub May 15, 2020. PMID: 32416070; PMCID: PMC7227586. May 28, 2020;181(5):1036-1045.e9. DOI: 10.1016/j.cell.2020.04.026.
[cited by applicant]
Zhou et al., “Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 patients”, Cell Host Microbe 27, 883-890 (2020).
[cited by applicant]
Wilk et al., “A Single-Cell Atlas of the Peripheral Immune Response in Patients with Severe COVID-19”, Nat. Med. 26, 1070-1076 (2020).
[cited by applicant]
Lee et al., “Immunophenotyping of COVID-19 and Influenza Highlights the Role of Type I Interferons in Development of Severe COVID-19”, Sci. Immunol. 5 (2020).
[cited by applicant]
Lucas et al., “Longitudinal Analyses Reveal Immunological Misfiring in Severe COVID-19”, Nature Journal, Jul. 27, 2020, https://doi.org/10.1038/s41586-020-2588-y.
[cited by applicant]
Park et al., “Type I Interferons and the Cytokine TNF Cooperatively Reprogram the Macrophage Epigenome to Promote Inflammatory Activation”, Nat. Immunol. 18, 1104-1116 (2017).
[cited by applicant]
Wang et al., Retrospective Multicenter Cohort Study Shows Early Interferon Therapy is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.07.005 (2020…
[cited by applicant]
Dinnon III et al., “A Mouse-Adapted Model of SARS-CoV-2 to Test COVID-19 Countermeasures.” Nature Journal. 2020; 586: 560-566.
[cited by applicant]
Vanderheiden et al., “Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.”, J Virol. 2020; 94: e00985-e001020.
[cited by applicant]
Feld et al., “Peginterferon Lambda for the Treatment of Outpatients with COVID-19: a Phase 2, Placebo-Controlled Randomised Trial”, Lancet Respir Med, (2021).
[cited by applicant]
Busnadiego et al., “Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2”, mBio 11, (2020).
[cited by applicant]
Stanifer et al., “Critical Role of Type III Interferon in Controlling SARS-CoV-2Infection in Human Intestinal Epithelial Cells”, Cell Rep 32, 107863 (2020).
[cited by applicant]
Galani et al., “Untuned Antiviral Immunity in COVID-19 Revealed by Temporal Type I/III Interferon Patterns and Flu Comparison”, Nat Immunol 22, 32-40 (2021).
[cited by applicant]
Felgenhauer et al., “Inhibition of SARS-CoV-2 by Type I and Type III Interferons”, J Biol Chem 295, 13958-13964 (2020).
[cited by applicant]
O'Brien et al., “Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-lambda to Treat Early Coronavirus Disease 2019”, Clinical Infectious Dis…
[cited by applicant]
Kerget et al., “Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19?”, Lung. 2020;198(5):777-784. doi:10.1007/s00408-020-00393-8.
[cited by applicant]
Watson et al., “Dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties”, Front Immunol. Jan. 19, 2021;11:622598. doi: 10.3389/fimmu.2020.622598.
[cited by applicant]
Dijkman et al., “Effective Interferon Lambda Treatment Regimen to Control Lethal MERS-CoV Infection in Mice.” J Virol. Jun. 8, 2022;96(11):e0036422. doi: 10.1128/jvi.00364-22. Epub May 19, 2022. PMID: 35588276; PMCID: P…
[cited by applicant]
Sullivan et al., “The Microbiome and the Pathophysiology of Asthma”, Respir Res 17, 163 (2016). https://doi.org/10.1186/s12931-016-0479-4.
[cited by applicant]
International Search Report for PCT Application PCT/EP2021056431, Apr. 23, 2021, 6 pages.
[cited by applicant]
Almond M. H., et al. “Obesity and Susceptibility to Severe Outcomes Following Respiratory Viral Infection”, Thorax. Jul. 2013, 68 (7); pp. 684-686. doi: 10.1136/thoraxjnl-2012-203009.
[cited by applicant]
Allen, AP, et al., “Bifidobacterium longum 1714 as a Translational Psychobiotic: Modulation of Stress, Electrophysiology and Neurocognition in Healthy Volunteers”, Translational Psychiatry, 2016, vol. 6, pp. 1-6.
[cited by applicant]
Amrouche T., et al., “Effects of Bifidobacterial Cytoplasm, Cell Wall and Exopolysaccharide on Mouse Lymphocyte Proliferation and Cytokine Production”, International Dairy Journal, 2006, 16; pp. 70-80.
[cited by applicant]
Bartlett N. W., et al., “Mouse Models of Rhinovirus Infection and Airways Disease”, Methods in Molecular Biology., 2015;1221, pp. 181-188. doi: 10.1007/978-1-4939-1571-2_14.
[cited by applicant]
Bouhnik Y., “Survie et Effets Chez L'homme des Bactéries Ingérées Dans Les Laits Fermentés”, Lait 1993, 73, pp. 241-247.
[cited by applicant]
Chasset, F., et al., Type I Interferons in Systems Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment, Frontiers in Pharmacology, 2021, vol. 1…
[cited by applicant]
Cole, S. L., et al., “Contribution of Innate Immune Cells to Pathogenesis of Severe Influenza Virus Infection”, Clinical Science, 2017, vol. 131, 269-83.
[cited by applicant]
Davidson S., et al., “Pathogenic Potential of Interferon αβ in Acute Influenza Infection”, Nature Communications, May 21, 2014; 5:3864, pp. 1-15.
[cited by applicant]
Davidson S., et al., “IFNλ Is a Potent Anti-Influenza Therapeutic Without The Inflammatory Side Effects of IFNα treatment”, EMBO Molecular Medicine., Sep. 1, 2016;8(9):pp. 1099-1112.
[cited by applicant]
Davidson, S.A., “Unique and Overlapping Actions of Type I and III IFNs in Influenza A Virus Infection and Implications for Therapy”, 2016, The Open University.
[cited by applicant]
Dunning, J., et al., “Seasonal and Pandemic Influenza: 100 Year of Progress, Still Much to Learn”, Mucosal Immunology, 2020, vol. 13, pp. 566-573.
[cited by applicant]
Durbin R. K., et al, “Interferon Induction and Function at the Muscol Surface”, Immunol Rev. Sep. 2013; 255 (1): pp. 25-39.
[cited by applicant]
Galani I.E., et al, “Interferon-λ Mediates Non-Redundant Front-Line Antiviral Protection Against Influenza Virus Infection Without Compromising Host Fitness”, Immunity, May 16, 2017; 46(5): pp. 875-890.
[cited by applicant]
Groeger D., et al., “Bifidobacterium infantis 35624 Modulates Host Inflammatory Processes Beyond The Gut”, Gut Microbes, Jul.-Aug. 2013; 4(4): pp. 325-339. doi: 10.4161/gmic.25487.
[cited by applicant]
Hartshorn K.L., et al., “Mechanisms of Anti-influenza Activity of Surfactant Proteins A and D: Comparison With Serum Collectins”, American Journal of Physiological Society, 1997; 273: L1156-L1166.
[cited by applicant]
Hartshorn K.L., et al., “Mechanism of Binding of Surfactant Protein D to Influenza A Viruses: Importance of Binding to Haemagglutinin to Antiviral Activity”, Biochem J 2000; 351 (Pt 2): pp. 449-458.
[cited by applicant]
Hawgood S. et al., “Pulmonary Collectins Modulate Strain-Specific Influenza A Virus Infection and Host Responses”, Journal of Virology, 2004; 78: pp. 8565-8572.
[cited by applicant]
Hewitt R., et al., “The Role of Viral Infections in Exacerbations of Chronic Obstructive Pulmonary Disease and Asthma”, Therapeutic Advances in Respiratory Disease, Apr. 2016;10(2): pp. 158-174. doi: 10.1177/17534658156…
[cited by applicant]
Holvoet, S., et al., “Characterization of Candidate Anti-Allergic Probiotic Strains in a Model of Th2-Skewed Human Peripheral Blood Mononuclear Cells”, Int Arch Allergy Immunol, 2013, vol. 161, pp. 142-154.
[cited by applicant]
Homayouni A. R., et al., “Can Probiotics Prevent or Improve Common Cold and Influenza?”, Nutrition 2019, 29; pp. 805-806.
[cited by applicant]
Ichikawa A., et al., “CXCL10-CXCR3 Enhances the Development of Neutrophil-Mediated Fulminant Lung Injury of Viral and Nonviral Origin”, American Journal of Respiratory and Critical Care Medicine, Jan. 1, 2013;187(1): pp…
[cited by applicant]
Ivashkiv L. B., et al., “Regulation of Type I Interferon Responses”, Nat Rev Immunol, Jan. 2014; 14(1): pp. 36-49.
[cited by applicant]
Iwabuchi, N., et al., “Effects of Intranasal Administration of Bifidobacterium longum BB536 on Mucosal Immune System in Respiratory Tract and Influenza Virus Infection in Mice”, Milk Science ,2009, vol. 58, No. 3; pp. 1…
[cited by applicant]
Iwabuchi, N., et al., “Immuno-modulating effects of Bifidobacterium longum BB536 and the mechanisms”, Milk Science, 2010, vol. 59, No. 3; pp. 275-281.
[cited by applicant]
Iwabuchi N., et al., “Oral Administration of Bifidobacterium longum Ameliorates Influenza Virus Infection in Mice”, Biol. Pharm. Bull , 2011. 34(8) pp. 1352-1355.
[cited by applicant]
Iwabuchi, N., et al., “Suppressive Effects of Bifidobacterium longum on the Production of Th2-attracting Chemokines Induced with T Cell-Antigen-Presenting Cell Interactions”, FEMS Immunol Med Microbiol, 2009, vol. 55, p…
[cited by applicant]
Jartti T., et al., “Role of Viral Infections in the Development and Exacerbation of Asthma in Children”, J Allergy Clin Immunol. Oct. 2017;140(4): pp. 895-906.
[cited by applicant]
Jounblat R., et al., “The Role of Surfactant Protein D in the Colonisation of the Respiratory Tract and Onset of Bacteraemia During Pneumococcal Pneumonia”, Respiratory Research, Oct. 28, 2005;6:126, pp. 1-12.
[cited by applicant]
Kawahara T., et al., “Consecutive Oral Administration of Bifidobacterium longum MM-2 Improves the Defense System Against Influenza Virus Infection by Enhancing Natural Killer Cell Activity in a Murine Model”, Microbiolo…
[cited by applicant]
Konieczna P., et al., “Bifidobacterium linfantis 35624 Administration Includes Foxp3 T Regulatory Cells in Human Peripheral Blood: Potential Role for Myeloid and Plasmacytoid Dendritic Cells”, Gut Microbiota, Mar. 2012;…
[cited by applicant]
Lazear H. M., et al., “Interferon-λ Immune Functions at Barrier Surfaces and Beyond”, Immunity, Jul. 21, 2015;43(1): pp. 15-28.
[cited by applicant]
Lei, W., et al., “Effect of Probiotics and Prebiotics on Immune Response to Influenza Vaccination in Adults: a Systematic Review and Meta-Analysis of Randomized Controlled Trials”, Nutrients, 2017, 9, 1175, pp. 1-17.
[cited by applicant]
Levine A. M., et al., “Surfactant Protein D Enhances Clearance of Influenza A Virus From the Lung in In Vivo Mouse Models”, The Journal of Immunology, 2001; 167: pp. 5868-5873.
[cited by applicant]
Levine A. M., et al., “Surfactant Protein-D Enhances Phagocytosis and Pulmonary Clearance of Respiratory Syncytial Virus”, American Journal of Respiratory Cell and Molecular Biology, Aug. 2004;31(2): pp. 193-199.
[cited by applicant]
Li W., et al., “Type I Interferon Induction During Influenza Virus Infection Increases Susceptibility to Secondary
[cited by applicant]
Lopez, P. et al., “Distinct Bifidobacerium Strains Drive Different Immune Responses In Vitro,” International Journal of Food Microbiology, 138, pp. 157-165 (2010).
[cited by applicant]
Medina, M. et al., “Differential Immunomodulatory Properties of Bifidobacterium logum Strains: Relevance to Probiotic Selection and Clinical Applications,” Clinical and Experimental Immunology, vol. 150, pp. 531-538 (20…
[cited by applicant]
Mendoza J. L.et al., “The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity”, Immunity, Mar. 21, 2017;46(3): pp. 379-392.
[cited by applicant]
Molenkamp G.C., et al., “Effects of Antibiotics on Metabolism of Peptidoglycan, Protein, and Lipids in Bifidobacterium bifidum subsp.
[cited by applicant]
Monticelli, L.A., et al., “Innate Lymphoid Cells Promote Lung-Tissue Homeostasis After Infection with Influenza Virus”, Nature Immunology, 2011, vol. 12, No. 11, pp. 1045-1056.
[cited by applicant]
Nakamura S. et al., “Synergistic Stimulation of Type I Interferons During Influenza Virus Coinfection Promotes
[cited by applicant]
Namba K., et al. “Effects of Bifidobacterium longum BB536 Administration of Influenza Infection, Influenza Vaccine Antibody Titer, and Cell-Mediated Immunity in the Elderly”, Biosci. Biotechnol. Biochem 2010. 74, pp. 93…
[cited by applicant]
O'Mahony C., et al., “Commensal-Induced Regulatory T Cells Mediate Protection Against Pathogen-Stimulated NF-kB Activation”, PLOS Pathogens, Aug. 2008, vol. 4, Issue 8, pp. 1-10.
[cited by applicant]
O'Mahony L., et al., “Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles”, Gastroenterology. Mar. 2005;128(3): pp. 541-551.
[cited by applicant]
Pegram, H.J., et al. “Activating and Inhibitory Receptors of Natural Killer Cells”, Immunology and Cell Biology, 2011, vol. 89, 216-24.
[cited by applicant]
Reading P.C., et al., “Collectin-Mediated Antiviral Host Defense of the Lung: Evidence From Influenza Virus Infection of Mice”, Journal of Virology, Nov. 1997;71: pp. 8204-8212.
[cited by applicant]
Rich H., et al., “The Role of Interferon Lambda During Influenza,
[cited by applicant]
Sastry K., et al., “Collectins: Pattern Recognition Molecules Involved in First Line Host Defense”, Current Opinion in Immunology, 5: pp. 59-66.
[cited by applicant]
Schiavi E., et al., “The Surface-Associated Exopolysaccharide of Bifidobacterium longum 35624 Plays an Essential Role in Dampening Host Proinflammatory Responses and Repressing Local TH17 Responses”, Applied and Environ…
[cited by applicant]
Sekine K., et al., “A New Morphologically Characterized Cell Wall Preparation (Whole Peptidoglycan) From Bifidobacterium infantis With a Higher Efficacy on the Regression of an Established Tumor in Mice”, Cancer Researc…
[cited by applicant]
Shahangian A. et al., “Type I IFNs Mediate Development of Postinfluenza Bacterial Pneumonia in Mice”, The Journal of Clinical Investigation, 2009;119: pp. 1910-1920.
[cited by applicant]
Shi X., et al., “Inhibition of the Inflammatory Cytokine Tumor Necrosis Factor-Alpha With Etanercept Provides Protection Against Lethal H1N1 Influenza Infection in Mice”, Critical Care, 2013; 17(6);R301, pp. 1-9.
[cited by applicant]
Steinke J. W., et al., “Immune Responses in Rhinovirus-Induced Asthma Exacerbations”, Curr Allergy Asthma Rep. Nov. 2016;16(11):78, pp. 1-14.
[cited by applicant]
Sun, J., “Effector T Cells Control Lung Inflammation During Acute Influenza Virus Infection by Producing IL-10”, Nature Medicine, 2009, vol. 15, No. 3, pp. 277-284.
[cited by applicant]
Tecle T., et al., “Inhibition of Influenza Viral Neuraminidase Activity by Collectins”, Archives of Virology 2007; 152: pp. 1731-1742.
[cited by applicant]
Thiel S., et al., “Structures and Functions Associated With the Group of Mammalian Lectins Containing Collagen-Like Sequences”, FEBS Letter 07262, Jun. 1989, vol. 250, No. 1, pp. 78-84.
[cited by applicant]
Vigerust D.J., et al., “N-Linked Glycosylation Attenuates H3N2 Influenza Viruses”, Journal of Virology, 2007; 81: pp. 8593-8600.
[cited by applicant]
Wack A., et al., “Guarding the Frontiers: the Biology of the Type III Interferons”, Nature Immunology. Jul. 2015, 16 (8): pp. 802-809.
[cited by applicant]
Wang W., et al., “Monoclonal Antibody Against CXCL-10/IP-10 Ameliorates Influenza A (H1N1) Virus Induced Acute Lung Injury”, Cell Research (2013) 23: pp. 577-580.
[cited by applicant]
World Health Organization 2007. “Global Surveillance, Prevention and Control of Chronic Respiratory Diseases, a Comprehensive Approach”, (Editors Jean Bousquet and Nikolai Khaltaev), pp. 1-155.
[cited by applicant]
Yang J. W., et al., “Corticosteroids for the Treatment of Human Infection With Influenza Virus: a Systematic Review and Meta-Analysis”, Clinical Microbiology and Infection, Oct. 2015; 21(10): pp. 956-963.
[cited by applicant]
Yeh, T., et al., “The Influence of Prebiotic and Probiotic Supplementation on Antibody Titers After Influenza Vaccination: a Systematic Review and Meta-Analysis of Randomized Controlled Trials”, Drug Design, Development…
[cited by applicant]
Zeleya H., et al., “Respiratory Antiviral Immunity and Immunobiotics: Beneficial Effects on Inflammation-Coagulation Interaction During Influenza Virus Infection”, Frontiers In Immunology, Dec. 2016, vol. 7, Article 633.
[cited by applicant]
Zhou X., et al., “Exacerbation of Chronic Obstructive Pulmonary Disease”, Cell Biochem Biophys, Nov. 2015; 73(2): pp. 349-355.
[cited by applicant]
International Search Report in PCT/EP2018/054914, dated Apr. 17, 2018 (3 pages).
[cited by applicant]
Mordstein, M. et al., “Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections”, Journal of Virology, vol. 84, Issue 11, pp. 5670-5677, Jun. 2010.
[cited by applicant]
Madan, T. et al., “A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples,” Am. J. Respir. Cell Mol. Biol., vol. 65, Iss. 1, p…
[cited by applicant]
Phetsouphanh, C. et al., “Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,” Nature Immunology, vol. 23, pp. 210-216 (Feb. 2022).
[cited by applicant]
Sposito, B. et al., “The interferon landscape along the respiratory tract impacts the severity of COVID-19,” Cell, vol. 184, pp. 4953-4968 (Sep. 2021).
[cited by applicant]
Talla, A. et al., “Persistent serum protein signatures define an inflammatory subset of long COVID,” Nature Communications, vol. 14, pp. 1-16 (Jun. 2023).
[cited by applicant]